Navigation Links
Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Date:6/14/2010

ermine what, if any, impact these data might have on other ongoing clinical trials evaluating the safety and efficacy of Nexavar.

"Bayer and Onyx are disappointed with these results, in particular, for patients who are suffering from this deadly disease," said Dr. Dimitris Voliotis, Vice President, Global Clinical Development Oncology, Bayer HealthCare.  "We are confident in our clinical trial program exploring Nexavar's potential in a variety of tumor types, including lung cancer.  Based on encouraging data from a recently presented prospective biomarker trial and Phase 2 signal-generating lung cancer studies, we believe it's critical to continue our evaluation of Nexavar in combination with targeted agents and as a monotherapy in later lines of treatment in lung cancer patients."

Nexavar is being evaluated by the companies and individual investigators in a variety of treatment settings for patients with non-small cell lung cancer, including a Phase 3 monotherapy study in the third- and fourth-line setting and Phase 2 studies in combination with other therapies in the second-line setting.

NExUS Trial Design

This Phase 3, randomized, double-blind, placebo-controlled study evaluated Nexavar (sorafenib) tablets in combination with the chemotherapeutic agents, gemcitabine and cisplatin, in treatment-naive non-small cell lung cancer patients.  The primary endpoint was overall survival, and secondary endpoints included progression-free survival, tumor response and safety.  Patients were randomized to receive 400 mg of oral Nexavar or matching placebo twice daily, in addition to gemcitabine and cisplatin for up to six cycles.  Subsequently, patients continued in a maintenance phase where Nexavar or placebo was administered as a single agent.  The study enrolled approximately 90
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
2. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
3. Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
4. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
5. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
6. Bayer HealthCare Pharmaceuticals, Inc. Announces Results of a Phase 3 Clinical Trial of Gadobutrol
7. Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
8. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
9. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
10. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
11. SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014   Assurex Health, a personalized medicine ... providers for behavioral health and chronic pain conditions, ... in equity financing from new and existing investors, ... and Chief Executive Officer. The financing ... Assurex Health,s GeneSight ®  products.  GeneSight,s ...
(Date:12/24/2014)... China , Dec. 23, 2014 ... pharmaceutical company that specializes in patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) today announced that the Company ... its Good Manufacturing Practice (GMP) certificate of TPI,s ... Drug Administration,s (CFDA). The public notice period is ...
(Date:12/24/2014)... , Dec. 23, 2014  Medical Science Liaisons ... the key link between the medical device industry and ... more in the coming years as the device industry ... According to research by benchmarking firm, Best Practices, ... gain an important edge is by harnessing new technology ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Role of Medical Science Liaisons Evolving in Medical Device Sector 2
... WIRE)--Jun 29, 2007 - Reata,Pharmaceuticals, Inc. today ... their lead anti-cancer agent, the,Synthetic Triterpenoid RTA ... caused by traditional cancer treatments. This,data was ... Multinational,Association of Supportive Care in Cancer (MASSC) ...
... /PRNewswire-FirstCall/ -- Advanced Life,Sciences Holdings, Inc. , today announced ... at 10:00 am (EDT) on Monday, July,2, 2007 to ... pivotal,Phase 3 clinical trials designed to assess the safety ... of community acquired pneumonia (CAP). , Conference Call Details: ...
Cached Medicine Technology:RTA 402 Shown to Protect Animals Against Toxicities of Standard,Cancer Treatments 2RTA 402 Shown to Protect Animals Against Toxicities of Standard,Cancer Treatments 3Advanced Life Sciences to Host Conference Call to Discuss Data From,Cethromycin's First of Two Phase 3 Pneumonia Trials 2
(Date:12/25/2014)... 25, 2014 When head lice hits a ... a frenzy to get rid of it while keeping it ... Coral Gables now have the solution right in their neighborhood: ... location, Lice Troopers provides full spectrum head lice screening and ... area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest ...
(Date:12/25/2014)... -- The risk of burns from fires and cooking ... be extra cautious, an expert says. "Between Thanksgiving ... in patients coming in with burns," said Dr. Steven ... Burn Center of Stony Brook University Hospital in New ... but if not careful, could quickly turn tragic," Sandoval ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... be closing in on a "fountain of youth" drug that ... of older adults, a new study suggests. Seniors received ... drug that targets a genetic signaling pathway linked to aging ... The experimental medication, a version of the ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as ... coolest mobile applications on the iOS, Android, and Windows markets. ... conducted the app review and shared with viewers how this ... The old saying goes, “A picture says a thousand words.” ... describe a single image, because each picture holds a unique ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Each year ... and 2 million hospital admissions across the nation (according ... ). The CDC’s National Hospital Ambulatory Medical Care ... a survey conducted in 2010. They estimated that there ... that resulted in a primary diagnosis of broken bone ...
Breaking Medicine News(10 mins):Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4
... One in eight new moms experience postpartum major depressive disorder ... 80 percent of women experience depressive symptoms postpartum, with one in ... Caused by multiple factors, including stress and hormone changes in the ... blues, to major depression and in rare circumstances, the most severe ...
... CRUZ, CA--The National Institute on Drug Abuse (NIDA) has awarded ... Berman, professor and chair of biomolecular engineering at the Jack ... Cruz. With the new five-year grant, Berman,s group ... August issue of the Journal of Virology . The ...
... Mass., Sept. 9 Echo Therapeutics, Inc. (OTC Bulletin ... Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous ... for transdermal drug delivery, announced today that it has ... 2009 Annual Global Investment Conference. Patrick T. Mooney, ...
... ... and Trademark office for knotless surgery tissue fixation to KFx Medical. , ... San Diego, CA (PRWEB) September 9, 2009 -- ... No. 7,585,311 by the United States Patent and Trademark office. The key patent covers a ...
... , More than 1.3 million Americans ... , , WASHINGTON, Sept. 9 Leading opponents of ... National Center for Policy Analysis (NCPA) and Salem Radio Network delivered the ... Now" petition to Congress at a rally held on Capitol Hill. , ...
... SAN DIEGO, Sept. 9 US Farms, Inc. (Pink ... that it has filed a Trademark Application in the United States, ... http://tarr.uspto.gov/servlet/tarr?regser=serial&entry=77821663 . , , ... a diversified Farming, Nursery and Wellness Company. The company grows, markets ...
Cached Medicine News:Health News:Prentice Women's Hospital Launches New Initiative to Better Identify and Address Postpartum Depression 2Health News:Prentice Women's Hospital Launches New Initiative to Better Identify and Address Postpartum Depression 3Health News:Prentice Women's Hospital Launches New Initiative to Better Identify and Address Postpartum Depression 4Health News:$3.5 million NIH grant supports AIDS vaccine research at UC Santa Cruz 2Health News:$3.5 million NIH grant supports AIDS vaccine research at UC Santa Cruz 3Health News:Echo Therapeutics Announces New Presentation Time at Rodman & Renshaw 2009 Annual Global Investment Conference 2Health News:KFx Medical Awarded Key Patent for Knotless Tissue Fixation and Double Row Rotator Cuff Surgery 2Health News:National Center for Policy Analysis and Salem Radio Network Deliver Million-Plus Signature Petition Opposing Government Run Health Care 2Health News:National Center for Policy Analysis and Salem Radio Network Deliver Million-Plus Signature Petition Opposing Government Run Health Care 3Health News:US Farms, Inc. Files Trademark Application for Aloe365 2
The Thermal pads were designed to simulate water immersion, the most effective method of transferring energy non-invasively....
This blanket is ideal for warming the large child or small adult during upper body surgery....
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
Medicine Products: